Abpro Collaborated with Celltrion to Develop and Commercialize ABP 102 for the Treatment of HER2+ Cancer
Shots:
- Abpro to receive ~$1.75B incl. an equity investment, development, and commercial milestones, and profit sharing globally
- Celltrion will be responsible for the development of ABP 102 upon the completion of in vitro studies by Abpro and also gets the commercialization rights globally
- The companies will combine Abpro’s Diversimmune and Multimab platform with Celltrion’s expertise in biology drug development globally to advance ABP 102 for the treatment of HER2+ breast, gastric, and pancreatic cancer. Additionally, Abpro’s ABP 102 showed the preliminary results of better efficacy and less toxicity over other therapies for the same indication
Ref: Businesswire | Image: Celltrion
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
